Castle Biosciences to Participate in Upcoming Investor Conferences
28 Ottobre 2024 - 12:00PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that its executive management is scheduled to present a
company overview at the following investor conferences next
month:
- Guggenheim Securities Healthcare Innovation Conference on Nov.
11, 2024, at 2:30 p.m. Eastern time.
- Stephens 26th Annual Investment Conference on Nov. 20, 2024, at
9:00 a.m. Eastern time.
Castle will also be available for one-on-one investor meetings
during the UBS Global Healthcare Conference on Nov. 12, 2024.
Meetings may be requested exclusively through UBS Investment
Bank.
Live audio webcasts of the Company’s presentations will be
available by visiting Castle Biosciences’ website at
https://ir.castlebiosciences.com/events-presentations/default.aspx.
Replays of the webcasts will be available following the conclusion
of the broadcasts.
About Castle Biosciences Castle Biosciences (Nasdaq:
CSTL) is a leading diagnostics company improving health through
innovative tests that guide patient care. The Company aims to
transform disease management by keeping people first: patients,
clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to help guide systemic therapy
selection for patients with moderate-to-severe atopic dermatitis,
psoriasis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR,
DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher,
IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are
trademarks of Castle Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241028608077/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Grafico Azioni Castle Biosciences (NASDAQ:CSTL)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Castle Biosciences (NASDAQ:CSTL)
Storico
Da Nov 2023 a Nov 2024
